J&J Darzalex shows treatment effect in mid-stage study in certain myelomas

Genmab A/S (OTCPK:GNMSF -2.3%) announces that a Phase 2 clinical trial, GRIFFIN, evaluating licensee Johnson & Johnson (JNJ +0.3%) unit Janssen Biotech’s Darzalex (daratumumab), combined with Celgene’s Revlimid (lenalidomide), Takeda’s Velcade (bortezomib) and dexamethasone (VRd), in newly diagnosed multiple myeloma patients eligible for high-dose chemo and autologous stem cell transplantation met the primary endpoint.

Patients receiving Darzalex + VRd showed a 42.4% rate of stringent complete responses compared to 32.0% for VRd alone.

No new safety signals were reported.

Darzalex is currently approved in the U.S. for multiple myeloma patients ineligible for autologous stem cell transplantation.

https://seekingalpha.com/news/3476311-j-and-js-darzalex-shows-treatment-effect-mid-stage-study-certain-mm-patients